DLB

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Corporation, Conference, DLB, Alzheimer's disease, Disease, Biomarker, Public expenditure, Translational Neurodegeneration, Completeness, Vance DeGeneres, Protein, Clinical trial, Quantitative electroencephalography, Therapy, NIA, SHIMMER, Cognition, Pharmaceutical industry

PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below.

Key Points: 
  • ET -
    PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Cognition scientists published two manuscripts and made 11 presentations at medical and scientific congresses in 2023, advancing the understanding of its foundational science and clinical implications.
  • “We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO .
  • Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
Wednesday, March 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

EVB Boosts EV Industry in the Nordic Region with Latest Solutions at Nordic EV Summit

Retrieved on: 
Friday, April 5, 2024
Electricity, Temperature, EV, Solar energy, Growth, DLB, BCP, Beny, OCPP, AC, EVB, WPS, Renewable energy

OSLO, Norway, April 5, 2024 /PRNewswire/ -- EVB, a sub-brand of Beny dedicated to smart EV charging solutions, showcased its latest products and technologies at the Nordic EV Summit held in Oslo, Norway.

Key Points: 
  • OSLO, Norway, April 5, 2024 /PRNewswire/ -- EVB, a sub-brand of Beny dedicated to smart EV charging solutions, showcased its latest products and technologies at the Nordic EV Summit held in Oslo, Norway.
  • At this summit, EVB emphasized its integrated solutions for both AC and DC charging, along with solar and energy storage, aimed at advancing the development of electric vehicles in the Nordic region.
  • To meet the rapidly growing demand for EV charging in the Nordic region, EVB has developed products tailored to market needs, covering both residential and commercial sectors, offering users an intelligent and worry-free charging experience.
  • EVB looks forward to collaborating with more Nordic partners to provide more convenient and efficient solutions, fully leveraging solar energy resources and contributing to the development of the EV industry.

Dolby Expanding the Best Way to Experience Movies by Making Dolby Vision and Dolby Atmos Available to All Premium Theater Exhibitors

Retrieved on: 
Tuesday, April 2, 2024
Atmos, Dolby Cinema, Sound, DLB, Caesars Palace, Colosseum, SAN, History, Dolby Atmos, Dolby Vision, Engineering, Life, Science, PLF, Cassette tape

Dolby Cinema is the ultimate moviegoing experience, providing a Dolby-designed environment that showcases the best implementation of Dolby Vision and Dolby Atmos.

Key Points: 
  • Dolby Cinema is the ultimate moviegoing experience, providing a Dolby-designed environment that showcases the best implementation of Dolby Vision and Dolby Atmos.
  • Dolby Cinema generates the highest average per screen box office amongst all premium large format (PLF) offerings.
  • This new solution gives exhibitors access to the visceral and awe-inspiring experience of Dolby Vision picture quality together with Dolby Atmos immersive sound – the same technologies that power Dolby Cinema, allowing audiences to see, hear and feel the film exactly as the filmmaker intended.
  • *
    Since the opening of the first Dolby Cinema in 2014, Dolby Cinema has grown rapidly, encompassing 28 exhibitor partners and 14 countries.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024
Axonal transport, Tauopathy, Neuron, CRVO, Cell biology, DLB, Plasma, Medical laboratory, MB, Phosphorylation, Overalls, FTD, GS, Vrije Universiteit Amsterdam, Publication, MAPK, Glial fibrillary acidic protein, GFAP, Axon, Brain, CNR, IW, EM, SDL, UCL, RAF kinase, Alpha-synuclein, Conference, Biomarker, AG, Lewy body, GBA, MD, Neurochemistry, PDF, JC, CP, Patient, Dementia, Basal forebrain, JA, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Dolby Showcases the Immersive power of Dolby Cinema in Latest "Love More" Global Brand Campaign

Retrieved on: 
Wednesday, February 28, 2024
Atmos, SAN, Dolby Vision, Senior, Sheeran, AMC, Love, Love Story, Dolby Cinema, DLB, Eastern Time Zone, Heart, Cassette tape

SAN FRANCISCO, Feb. 28, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, is launching the next chapter of the " Love More in Dolby " global brand campaign with a new commercial celebrating the transformative theatrical experience of watching movies in Dolby Vision and Dolby Atmos at Dolby Cinema.

Key Points: 
  • SAN FRANCISCO, Feb. 28, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, is launching the next chapter of the " Love More in Dolby " global brand campaign with a new commercial celebrating the transformative theatrical experience of watching movies in Dolby Vision and Dolby Atmos at Dolby Cinema.
  • Watching movies at Dolby Cinema unlocks the full emotional impact of every film, allowing audiences to be fully immersed in the story.
  • "Dolby Cinema transports fans into the heart of their favorite stories with the combined immersive experience of Dolby Vision and Dolby Atmos," said Todd Pendleton, Senior Vice President and Chief Marketing Officer, Dolby Laboratories.
  • Directed by GRAMMY®-nominated music video director and filmmaker Colin Tilley, the commercial explores the transformative experience of watching movies with Dolby Cinema.

Dolby Laboratories Senior Vice President and Chief Financial Officer Robert Park and Senior Vice President of Entertainment John Couling to Host Fireside Chat at the Morgan Stanley Technology, Media & Telecom Conference

Retrieved on: 
Tuesday, February 27, 2024
Entertainment, SAN, Senior, DLB, Conference

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced that Robert Park, Senior Vice President and Chief Financial Officer, and John Couling, Senior Vice President of Entertainment will host a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco, California on Tuesday, March 5, 2024, at 8:45 AM PT (11:45 AM ET).

Key Points: 
  • SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced that Robert Park, Senior Vice President and Chief Financial Officer, and John Couling, Senior Vice President of Entertainment will host a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco, California on Tuesday, March 5, 2024, at 8:45 AM PT (11:45 AM ET).
  • A live webcast and replay of the event will be available at http://investor.dolby.com .

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Retrieved on: 
Monday, February 12, 2024
MRI, International, MD, TID, CRVO, Manuscript, DLB, EEG, Patient, Dementia, Journal, Lewy body, Brain, Pharmaceutical industry

BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, announced that data from the AscenD-LB Phase 2a trial evaluating treatment with neflamapimod in patients with dementia with Lewy bodies (DLB) were published online in the Journal of Prevention of Alzheimer’s Disease (JPAD). The published manuscript titled “Phase 2a learnings incorporated into RewinD-LB, a Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies,” is available online.

Key Points: 
  • The published manuscript titled “Phase 2a learnings incorporated into RewinD-LB, a Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies,” is available online .
  • “The publication of the EEG and MRI results round out the Phase 2a data that supports the advancement of neflamapimod into late-stage development as a treatment for DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • Our RewinD-LB trial, which we believe is derisked through the incorporation of learnings outlined in the publication, is highly powered and designed to stratify patients most likely to benefit from neflamapimod.
  • As evident in the table, compared to the response in the overall patient population, the magnitude of the neflamapimod treatment effect vs. placebo is substantially higher in the pure DLB patient population.

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Retrieved on: 
Wednesday, February 7, 2024
ARD International Music Competition, Growth, Wesleyan University, Biophysical chemistry, Chairperson, Harvard University, DLB, Caregiver, Medicinal chemistry, Patient, Laboratory, CRVO, Vertex Pharmaceuticals, Philosophy, Inflammation, Drug design, Doctorate, Brain, Immunology, Drug development, Merck, Lewy body, Merck & Co., Dementia, Master, Pharmaceutical industry

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical company leadership experience to CervoMed as it progresses toward an important inflection point. Topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) is expected in the second half of 2024. The Board Chair position was formerly held by CervoMed co-founder Dr. Sylvie Gregoire, who will continue to serve as a director.

Key Points: 
  • The Board Chair position was formerly held by CervoMed co-founder Dr. Sylvie Gregoire, who will continue to serve as a director.
  • “It is a pleasure to welcome Joshua, the founder of Vertex and an esteemed industry leader, to our Board of Directors,” said John Alam, M.D., Chief Executive Officer of CervoMed.
  • Dr. Joshua Boger is an industry veteran who has served in multiple scientific and business leadership roles in his 40+ year career.
  • He continued to serve on the Vertex Board and Chair Vertex’s Science & Technology Committee until 2017.